In keeping with the human data, combining a muCD20-TCB with mu4-1BB-FAP or muFAP-IL2v significantly improved DLBCL cell killing compared with TCB treatment alone (Figure 13, A and B and Supplemental Figure 9, H and I). This evidence concerns the gene FAP and diffuse large B-cell lymphoma.